-
BioCentury launched at H&Q
BioCentury launched at H&Q
See BioCentury, Jan. 11, 1993 -
Centocor halts Centoxin sepsis trial
-
BIO formed
-
Human Genome Sciences and SmithKline sign the first big genomics deal
-
Chiron's Betaseron first approved beta interferon
-
Clinton healthcare reform bill introduced
-
Millennium starts string of large genomics deals (Roche)
-
David Blech bank fails
-
ReoPro approved (Sweden), changing angioplasty treatment
-
First HIV protease inhibitor, Roche's Invirase
-
MedImmune's RespiGam approved to treat RSV
-
Qiagen, first German biotech IPO
-
Dolly the sheep cloned
-
Fenfluramine drugs withdrawn
-
FDA Modernization Act becomes law
-
British Biotech meltdown
-
Celgene's Thalomid approved for leprosy
-
First targeted cancer therapy, Genentech's Herceptin
-
FDA approves first TNF alpha inhibitor, Immunex's Enbrel, for RA
-
Gates Foundation begins large-scale funding of neglected diseases
-
U.K.'s NICE created
-
Roche exercises option to acquire remainder of Genentech
-
Genentech: 2nd coming
-
J&J buys Centocor for $4.9B
-
Jesse Gelsinger dies in gene therapy trial
-
IPO window explodes
-
Genomics bubble bursts on erroneous reports that genes can't be patented
-
Human genome sequenced
-
Reg FD takes effect
-
May 01 - FDA approves Novartis' Gleevec, changing CML from fatal to chronic
-
Bush compromise on stem cells
-
9/11 and anthrax attacks spur biodefense
-
Amgen acquires Immunex for $10.4B
-
ImClone scandal
-
First biotech financing >$1B, Amgen $2.5B convert
-
Sarbanes-Oxley becomes law
-
AnGes, first Japanese biotech IPO
-
Spitzer Wall Street deal splits bankers and sellside
-
SARS first reported in Asia
-
Biogen, Idec merge
-
Yamanouchi, Fujisawa merge to form Astellas
-
Biocon IPO marks emergence of Indian biotech
-
Germany forms IQWiG to assess cost-benefit
-
Merck pulls Vioxx
-
California passes $3B stem cell initiative (Prop. 71)
-
Biogen Idec, Elan suspend Tysabri sales
-
Europe creates biosimilar pathway
-
Sanofi's Ketek prompts FDA to reassess standards for antibiotics for community-acquired infections
-
EC approves first biosimilar, Sandoz's Omnitrope
-
Tysabri relaunched
-
First vaccine to prevent cancer, Merck's Gardasil HPV vaccine
-
FDA adds black box to ESA labels
-
AstraZeneca buys MedImmune for $15.6B
-
Avandia meta-analysis creates fear of CV side effects from diabetes drugs
-
NICE agrees to pay for performance deal for Velcade
-
FDA Amendments Act of 2007 becomes law
-
FDA issues CV guidance for diabetes drugs
-
Obama lifts ban on government funding of embryonic stem cell research
-
Roche buys Genentech, again
-
WHO declares H1N1 a pandemic
-
Obama signs Patient Protection and Affordable Care Act
-
First cancer immunotherapy, Dendreon's Provenge
-
Sanofi acquires Genzyme for $20.1B + CVR
-
First HCV protease inhibitors, Merck's Victrelis and Vertex's Incivek
-
First simultaneous approval of Rx-Dx combination since Herceptin, Zelboraf and companion Dx from Roche and Daiichi Sankyo for melanoma